BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND POU2AF1, OBF1, 5450, ENSG00000110777, BOB1, OCAB, Q16633, OBF-1 AND Treatment
6 results:

  • 1. T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion.
    Morton LT; Wachsmann TLA; Meeuwsen MH; Wouters AK; Remst DFG; van Loenen MM; Falkenburg JHF; Heemskerk MHM
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288464
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A B-cell developmental gene regulatory network is activated in infant AML.
    Bolouri H; Ries R; Pardo L; Hylkema T; Zhou W; Smith JL; Leonti A; Loken M; Farrar JE; Triche TJ; Meshinchi S
    PLoS One; 2021; 16(11):e0259197. PubMed ID: 34793513
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Lymphocyte-depleted classic Hodgkin lymphoma with primary extranodal disease: Two cases that highlight the combination of immunodeficiency and immune escape in the pathogenesis.
    Tsuyuki Y; Kohno K; Inagaki Y; Sakai Y; Kosugi H; Takahashi E; Suzuki Y; Shimada S; Kato S; Takahara T; Satou A; Shimoyama Y; Nakamura S; Asano N; Sakakibara A
    J Clin Exp Hematop; 2021; 61(3):173-179. PubMed ID: 34511545
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Trends and Patterns of Disparities in Cancer Mortality Among US Counties, 1980-2014.
    Mokdad AH; Dwyer-Lindgren L; Fitzmaurice C; Stubbs RW; Bertozzi-Villa A; Morozoff C; Charara R; Allen C; Naghavi M; Murray CJ
    JAMA; 2017 Jan; 317(4):388-406. PubMed ID: 28118455
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor bob1.
    Jahn L; Hombrink P; Hagedoorn RS; Kester MG; van der Steen DM; Rodriguez T; Pentcheva-Hoang T; de Ru AH; Schoonakker MP; Meeuwsen MH; Griffioen M; van Veelen PA; Falkenburg JH; Heemskerk MH
    Blood; 2017 Mar; 129(10):1284-1295. PubMed ID: 28053195
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Very late relapse of PTLD 10 yr after allogeneic HSCT and nine yr after stopping immunosuppressive therapy.
    Helgestad J; Rosthøj S; Pedersen MH; Johansen P; Iyer V; Østergaard E; Heilmann C
    Pediatr Transplant; 2014 Feb; 18(1):E35-9. PubMed ID: 24168387
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.